,
Pouget, Jean-Pierre
Konijnenberg, Mark
Eberlein, Uta
Glatting, Gerhard
Gabina, Pablo Minguez
Herrmann, Ken
Holm, Søren
Strigari, Lidia
van Leeuwen, Fijs W. B.
Lassmann, Michael
Article History
First Online: 6 September 2022
Declarations
:
: Institutional Review Board approval was not required because the paper is an editorial.
: Not applicable.
: M.L. has received research grants by IPSEN Pharma and Nordic Nanovector.K.H. reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal and fees from Janssen, outside the submitted work.J-P.P., M.K., U.E., G.G., P.M.G., S.H., L.S., and F.v.L. have no conflicts of interest to declare.M.L. is member of the EANM board.The following authors are members of the EANM committees:• Radiation Protection (U.E., S.H.)• Oncology (M.K., K.H.)• Dosimetry (P.M.G.)• Translational Molecular Imaging & Therapy (J-P.P., F.v.L.)